<b><i>Introduction:</i></b> Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients’ persistence on treatment, in a real-world setting. <b><i>Methods:</i></b> Data were extracted from de-identified electronic medical records from an obesity management clinic in Switzerland. Changes in body weight and blood pressure were evaluated in the full cohort (<i>N</i> = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (<i>n</i> = 236), 7 months (<i>n</i> = 159), or 12 months (<i>n</i> = 71). <b><i>Results:</i></b> Median persistence on liraglutide was 6.8 months. Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg. Mean 7-month weight change from baseline in the full cohort was −4.1 kg (95% confidence interval: −5.0, −3.2; <i>p</i> &#x3c; 0.001; −4.2%). Weight change was −4.4 kg (−4.7%) in the ≥4-month persistence subgroup at 4 months, −5.1 kg (−5.3%) in the ≥7-month persistence subgroup at 7 months, and −7.5 kg (−7.1%) in the ≥12-month persistence subgroup at 12 months (all <i>p</i> &#x3c; 0.001). In the full cohort, 40% and 14% of patients lost ≥5% and &#x3e;10% of body weight at 7 months, respectively. Weight loss did not differ significantly according to history of bariatric surgery (<i>p</i> = 0.94). Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; <i>p</i> = 0.018), with no significant changes in systolic blood pressure. Approximately two-thirds of patients did not have health insurance that could cover the cost of liraglutide. <b><i>Conclusion:</i></b> In a real-world setting with low insurance coverage and with most patients not reaching the recommended maintenance dose of 3.0 mg, the use of liraglutide, in combination with diet and exercise, was associated with clinically meaningful weight loss.

end of data collection, death or transfer out of practice, whichever came first. Age-, sex-and comorbidity-adjusted hospitalisation rate ratios (RRs) and hazard ratios (HRs) were calculated. Results: Data from 28,335 patients with HF and 85,005 controls were examined (mean age 75.4 years; 45.4% women). At baseline, patients with HF had higher cardiovascular disease (CVD)-related and metabolic medication use (83.7% vs 50.2%) and a higher Charlson Comorbidity Index score (2.03 vs 1.30) than controls. CVD-related comorbidities were more common among patients with HF than controls, whereas malignancies, liver and rheumatological diseases were similarly prevalent in both groups. All-cause hospitalisation rate (RR, 1.90; 95% CI, 1.88-1.91; p< 0.001) and risk of hospitalisation (HR, 1.81; 95% CI, 1.78-1.85; p< 0.001) were significantly higher in individuals with HF than controls. A greater proportion of individuals with HF than controls had died or were lost to follow-up after 5 years (34.6% vs 20.4%). ConClusions: Increased hospitalisation rates and morbidity in patients with HF versus an age-and sex-matched population without HF demonstrate the burden of HF on the healthcare system in England.